AR071262A2 - Peptidos derivados de una proteina de vih-1gagp24, composiciones de vacunas kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih - Google Patents
Peptidos derivados de una proteina de vih-1gagp24, composiciones de vacunas kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vihInfo
- Publication number
- AR071262A2 AR071262A2 ARP080105262A ARP080105262A AR071262A2 AR 071262 A2 AR071262 A2 AR 071262A2 AR P080105262 A ARP080105262 A AR P080105262A AR P080105262 A ARP080105262 A AR P080105262A AR 071262 A2 AR071262 A2 AR 071262A2
- Authority
- AR
- Argentina
- Prior art keywords
- xaa
- ala
- gly
- leu
- thr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Extraction Or Liquid Replacement (AREA)
Abstract
Péptido derivado de una proteína de VIH-1 gagp24, que comprende una secuencia de aminoácidos seleccionada de: (1) Xaa1 Ala Xaa3 Xaa4 Xaa5 Ala Xaa7 Xaa8 Xaa9 Leu Leu Xaa12 Xaa13 Xaa14 -Z- Xaa15 Xaa16 His GIn Xaa19 Ala Xaa21 Xaa22 (SEC ID N°: 9) donde Xaa en posicion 1 es Tyr, Trp, Phe o Gly, Xaa en posicion 3 es Thr, Ala, Val, Ile o Leu, Xaa en posicion 4 es Pro o Ser, Xaa en posicion 5 es GIn, His, Gly, Thr, Ser o Tyr, Xaa en posicion 7 es Leu, Ile o Val, Xaa en posicion 8 es Asn o Tyr, Xaa en posicion 9 es Thr, Met, Leu o Ala, Xaa en posicion 12 es Ser, Thr o Asn, Xaa en posicion 13 es Thr, Ile, Val o Ala, Xaa en posicion 14 es Val o Ile, Xaa en posicion 15 es Gly o ninguno, Xaa en posicion 16 es Gly o ninguno, Xaa en posicion 19 es Ala o Gly, Xaa en posicion 20 es Ala, Xaa en posicion 21 es Met, Leu, Cys o ninguno, Xaa en posicion 22 es Gln, Glu, His, Gly o ninguno donde el enlace -Z- es opcional y tiene el significado PEG, PEG modificado y/o [Gly]n, donde n = 1, 2 o 3, (ii) Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Gly Xaa9 Leu Val -Z- Tyr Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Ala Xaa23 Xaa24 Xaa25 Xaa26 (SEQ ID N°: 4) donde los aminoácidos de la cadena tienen los siguientes significados: Xaa en posicion 1 es Pro, Tyr o Phe, Xaa en posicion 2 es Ile, Val o Leu, Xaa en posicion 3 es Ile, Ala, Val, Met o Leu, Xaa en posicion 4 es GIn, Ser, Thr o Val, Xaa en posicion 5 es Asn, Asp o Thr, Xaa en posicion 6 es Ile, Ala, Leu o Met, Xaa en posicion 7 es GIn, Glu, Lys o Gly, Xaa en posicion 9 es Gln o Ile, Xaa en posicion 13 se omite, Xaa en posicion 14 es Ala, Ser, Asn, Val o Pro, Xaa en posicion 15 es Ile, Leu, Met o Val, Xaa en posicion 16 es Ser o Thr, Xaa en posicion 17 es Pro o Ala, Xaa en posicion 18 es Arg o Lys, Xaa en posicion 19 es Thr o Ser, Xaa en posicion 20 es Leu o Ser, Xaa en posicion 21 es Asn, Phe o Val, Xaa en posicion 23 es Trp, Tyr, Gly o ninguno, Xaa en posicion 24 es Val, Leu, Gly o ninguno, Xaa en posicion 25 es Lys, Arg, Gly o ninguno, Xaa en posicion 26 es Val, Ala, Cys, Gly o ninguno donde -Z- es un enlace opcional y tiene el significado PEG, PEG modificado y/o [Gly]n donde n = 1, 2 o 3, (iii) Xaa1 Xaa2 Ala Leu Ala Gly Xaa7 Xaa8 Xaa9 Leu Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 (SEQ ID N°: 15) donde Xaa en posicion 1 es Trp o Tyr, Xaa en posicion 2 es Ser o Ala, Xaa en posicion 7 es Thr, Ala o Ser, Xaa en posicion 8 es Ser o Thr, Xaa en posicion 9 es Ser o Thr, Xaa en posicion 11 es Leu, Pro, Val o Gln, Xaa en posicion 12 es Gln, Ala o His, Xaa en posicion 13 es Glu o Gly, Xaa en posicion 14 es Gln o His, Xaa en posicion 15 es Ile, Leu, Val o Met, Xaa en posicion 16 es Gly, Ala, GIn, Thr, Asn, Arg, His o Ile, Xaa en posicion 17 es Trp o Tyr, Xaa en posicion 18 es Thr, Met, Leu o Ile, Xaa en posicion 19 es Thr o Ser, Xaa en posicion 20 es Cys, Gly o ninguno, Xaa en posicion 21 es Gly o ninguno y donde los extremos terminales de las secuencias pueden ser grupos carboxilo o amino libres, amidas, acilos, acetilos o sales de los mismos, dos o más de los residuos Cys pueden formar parte de un enlace de disulfuro intercadena, un puente -S-(CH2)p-S- o un puente -(CH2)p donde p = 1-8 opcionalmente intervenido por uno o más heteroátomos como O, N y S y/o dichas secuencias peptídicas están inmovilizadas a un soporte solido. Composiciones de vacunas, kit de inmunoensayo y un método para detectar anticuerpos inducidos por VIH.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20004413A NO314588B1 (no) | 2000-09-04 | 2000-09-04 | HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071262A2 true AR071262A2 (es) | 2010-06-09 |
Family
ID=19911533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104196A AR033998A1 (es) | 2000-09-04 | 2001-09-04 | Peptidos de vih, antigenos, composiciones de vacunas, kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih |
| ARP080105262A AR071262A2 (es) | 2000-09-04 | 2008-12-03 | Peptidos derivados de una proteina de vih-1gagp24, composiciones de vacunas kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104196A AR033998A1 (es) | 2000-09-04 | 2001-09-04 | Peptidos de vih, antigenos, composiciones de vacunas, kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7009037B2 (es) |
| EP (2) | EP1878742A3 (es) |
| JP (2) | JP2004508381A (es) |
| CN (2) | CN101104636A (es) |
| AR (2) | AR033998A1 (es) |
| AT (1) | ATE406380T1 (es) |
| AU (3) | AU2001282706B2 (es) |
| BR (1) | BR0114036A (es) |
| CA (1) | CA2421193A1 (es) |
| DE (1) | DE60135564D1 (es) |
| EA (1) | EA006308B1 (es) |
| ES (1) | ES2312465T3 (es) |
| HU (1) | HUP0303134A3 (es) |
| MY (1) | MY136081A (es) |
| NO (1) | NO314588B1 (es) |
| NZ (2) | NZ524556A (es) |
| SK (1) | SK287917B6 (es) |
| WO (1) | WO2002020554A2 (es) |
| ZA (1) | ZA200301740B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004503205A (ja) | 2000-02-04 | 2004-02-05 | デューク・ユニバーシティー | ヒト免疫不全ウイルスワクチン |
| CA2619709C (en) * | 2005-08-26 | 2012-05-01 | Novo Nordisk A/S | A method of modifying a macromolecular system |
| ATE425204T1 (de) * | 2005-08-26 | 2009-03-15 | Novo Nordisk As | Verfahren zur modifizierung eines makromolekularen systems |
| FI120376B (fi) * | 2007-01-17 | 2009-09-30 | Next Biomed Technologies Nbt O | Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi |
| FI120349B (fi) | 2007-03-07 | 2009-09-30 | Next Biomed Technologies Nbt O | Menetelmä fuusiopolypeptidin valmistamiseksi |
| US8431153B2 (en) | 2008-09-09 | 2013-04-30 | Celebrity Biogens, Llc | Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same |
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| US9733242B2 (en) | 2012-10-07 | 2017-08-15 | Sevident, Inc. | Devices for capturing analyte |
| US9910040B2 (en) | 2012-07-09 | 2018-03-06 | Sevident, Inc. | Molecular nets comprising capture agents and linking agents |
| FR2957933B1 (fr) * | 2010-03-24 | 2012-04-27 | Seppic Sa | Vaccin vivant pour maladies aviaires |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| JP6294076B2 (ja) * | 2011-01-06 | 2018-03-14 | ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ | 多量体ペプチド |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| IN2014KN02769A (es) * | 2012-06-06 | 2015-05-08 | Bionor Immuno As | |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| CA2907454C (en) | 2013-03-21 | 2021-05-04 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| US10450343B2 (en) | 2013-03-21 | 2019-10-22 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3319631A4 (en) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| CN116064678A (zh) | 2016-01-15 | 2023-05-05 | 美国基因技术国际有限公司 | 用于活化γ-δT细胞的方法和组合物 |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| WO2017139065A1 (en) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| WO2017156311A2 (en) | 2016-03-09 | 2017-09-14 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT |
| AU2017292582C1 (en) * | 2016-07-08 | 2021-11-11 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| EP3487507A4 (en) | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| JP2020524996A (ja) | 2017-06-16 | 2020-08-27 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | ヒトガンマデルタｔ細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
| US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
| RU2727673C1 (ru) * | 2019-08-09 | 2020-07-22 | Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства | Антитела против белка р17 ВИЧ-1 субтипа А |
| GB2610556A (en) * | 2021-09-02 | 2023-03-15 | 113 Botanicals Ltd | Extraction |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ235538A (en) * | 1989-10-12 | 1992-06-25 | Viral Technologies Inc | Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera |
| SE468168B (sv) | 1990-02-20 | 1992-11-16 | Replico Medical Ab | Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov |
| DE4039925A1 (de) * | 1990-12-14 | 1992-06-17 | Behringwerke Ag | Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung |
| SE9101863D0 (sv) * | 1991-06-13 | 1991-06-13 | Replico Medical Ab | Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar |
| US6525173B1 (en) | 1997-01-02 | 2003-02-25 | Universidade Federal De Minas Gerais | Process for expression and production of recombinant protein hybrid protein (p24/p17) derived from human immunodeficiency viruses (HIV-1) |
| GB9703802D0 (en) * | 1997-02-24 | 1997-04-16 | Kingsman Susan M | Anti-hiv peptides and proteins |
| US5972339A (en) * | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
| US6534482B1 (en) * | 1998-05-13 | 2003-03-18 | Epimmune, Inc. | Expression vectors for stimulating an immune response and methods of using the same |
| NO311807B1 (no) * | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
-
2000
- 2000-09-04 NO NO20004413A patent/NO314588B1/no not_active IP Right Cessation
-
2001
- 2001-09-03 CA CA002421193A patent/CA2421193A1/en not_active Abandoned
- 2001-09-03 ZA ZA200301740A patent/ZA200301740B/en unknown
- 2001-09-03 US US10/129,331 patent/US7009037B2/en not_active Expired - Fee Related
- 2001-09-03 NZ NZ524556A patent/NZ524556A/en not_active IP Right Cessation
- 2001-09-03 BR BR0114036-1A patent/BR0114036A/pt not_active IP Right Cessation
- 2001-09-03 AU AU2001282706A patent/AU2001282706B2/en not_active Ceased
- 2001-09-03 HU HU0303134A patent/HUP0303134A3/hu unknown
- 2001-09-03 CN CNA2006101517487A patent/CN101104636A/zh active Pending
- 2001-09-03 EA EA200300336A patent/EA006308B1/ru not_active IP Right Cessation
- 2001-09-03 CN CNB018157424A patent/CN1282656C/zh not_active Expired - Fee Related
- 2001-09-03 EP EP07014954A patent/EP1878742A3/en not_active Withdrawn
- 2001-09-03 EP EP01961444A patent/EP1322665B1/en not_active Expired - Lifetime
- 2001-09-03 AT AT01961444T patent/ATE406380T1/de not_active IP Right Cessation
- 2001-09-03 DE DE60135564T patent/DE60135564D1/de not_active Expired - Lifetime
- 2001-09-03 NZ NZ535148A patent/NZ535148A/en not_active IP Right Cessation
- 2001-09-03 AU AU8270601A patent/AU8270601A/xx active Pending
- 2001-09-03 SK SK402-2003A patent/SK287917B6/sk not_active IP Right Cessation
- 2001-09-03 WO PCT/NO2001/000362 patent/WO2002020554A2/en not_active Ceased
- 2001-09-03 JP JP2002525174A patent/JP2004508381A/ja active Pending
- 2001-09-03 ES ES01961444T patent/ES2312465T3/es not_active Expired - Lifetime
- 2001-09-04 MY MYPI20014139A patent/MY136081A/en unknown
- 2001-09-04 AR ARP010104196A patent/AR033998A1/es active IP Right Grant
-
2005
- 2005-08-26 US US11/211,576 patent/US7612168B2/en not_active Expired - Fee Related
-
2007
- 2007-06-13 AU AU2007202739A patent/AU2007202739B2/en not_active Ceased
-
2008
- 2008-12-03 AR ARP080105262A patent/AR071262A2/es not_active Application Discontinuation
-
2011
- 2011-06-08 JP JP2011128389A patent/JP2011219481A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071262A2 (es) | Peptidos derivados de una proteina de vih-1gagp24, composiciones de vacunas kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih | |
| AR033997A1 (es) | Peptidos regulatorios y auxiliares de vih, antigenos, composiciones de vacunas, kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih | |
| ES2514615T3 (es) | Proteínas de dominio Kunitz inhibidores de calicreína y ácidos nucleicos que codifican las mismas | |
| ES2297902T5 (es) | Compuestos novedosos agonistas de exendina | |
| PE20250556A1 (es) | Agonista triple de receptores de glucagon/glp-1/gip | |
| PE20060713A1 (es) | Polipeptidos moduladores del peptido 1 similar al glucagon humano | |
| JP2019504057A5 (es) | ||
| JP2019533442A5 (es) | ||
| Klausner et al. | Postischemic renal injury is mediated by neutrophils and leukotrienes | |
| JP5465648B2 (ja) | 臓器及び組織の保存方法 | |
| CA2373721A1 (en) | Compounds that bind her2 | |
| Waterhouse et al. | Alterations of sperm DNA integrity during cryopreservation procedure and in vitro incubation of bull semen | |
| CA2048910A1 (en) | Antimicrobial peptides active against plant pathogens, their method of use and various screening methods pertaining thereto | |
| ES2144394T3 (es) | Polipeptidos y peptidos recombinantes, acidos nucleicos que los codifican y utilizacion de dichos polipeptidos y peptidos para el diagnostico de la tuberculosis. | |
| CN103025155B (zh) | 器官冷藏组合物 | |
| JP2023521491A5 (es) | ||
| Cornwall et al. | Induction and enhancement of progressive motility in hamster caput epididymal spermatozoa | |
| AU1103700A (en) | Tgf-beta superfamily mutant members, including morphogenic proteins | |
| Wysocki | Zinc-binding proteins from boar seminal plasma--isolation, biochemical characteristics and influence on spermatozoa stored at 4° C | |
| EP1223805A1 (en) | Method for cryopreservation of teleostei semen | |
| GB2640988A (en) | Amylin analogues | |
| ATE332921T1 (de) | Neue peptidzusammensetzungen und deren verwendung,insbesondere zur herstellung von pharmazeutischen zusammensetzungen mit wirkung gegen das hepatitis-c-virus | |
| Sui et al. | Ice-free cryopreservation of heart valve tissue: The effect of adding MitoQ to a VS83 formulation and its influence on mitochondrial dynamics | |
| Spector et al. | 5-Hydroxytryptamine in acute inflammation | |
| CO2024010813A2 (es) | Inhibidor de tsp1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |